Iris melanoma
disease diseaseOn this page
Also known as iris malignant melanomairis melanoma (disease)malignant melanoma of irismalignant melanoma of the irismelanoma (disease) of irismelanoma of irismelanoma of the iris
Summary
Iris melanoma (MONDO:0004064) is a cancer and 15 clinical trials. Top therapeutic interventions include dacarbazine, sargramostim, and sunitinib. A subtype of iris cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 15
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | iris melanoma |
| Mondo ID | MONDO:0004064 |
| DOID | DOID:6994 |
| NCIT | C9088 |
| SNOMED CT | 255012009 |
| UMLS | C0346373 |
| MedGen | 87559 |
| GARD | 0023802 |
| Anatomy (UBERON) | UBERON:0001769 |
| Is cancer (heuristic) | yes |
Also known as: iris malignant melanoma · iris melanoma · iris melanoma (disease) · malignant melanoma of iris · malignant melanoma of the iris · melanoma (disease) of iris · melanoma of iris · melanoma of the iris
Disease family
An umbrella term covering 3 Mondo subtypes.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › uveal cancer › iris cancer › iris melanoma
Related subtypes (3): ciliary body cancer, aniridia 2, aniridia 3
Subtypes (3): malignant ciliary body melanoma, intermediate cell type iris melanoma, iris spindle cell melanoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 15.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01989572 | PHASE3 | COMPLETED | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery |
| NCT02068586 | PHASE2 | ACTIVE_NOT_RECRUITING | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma |
| NCT00085189 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma |
| NCT00089063 | PHASE2 | COMPLETED | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma |
| NCT00121225 | PHASE2 | COMPLETED | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma |
| NCT00243061 | PHASE2 | COMPLETED | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma |
| NCT00288041 | PHASE2 | COMPLETED | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma |
| NCT00329641 | PHASE2 | COMPLETED | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
| NCT00450255 | PHASE2 | COMPLETED | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| NCT01100528 | PHASE2 | COMPLETED | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance |
| NCT01143402 | PHASE2 | COMPLETED | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye |
| NCT01413191 | PHASE2 | COMPLETED | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye |
| NCT05628883 | PHASE1 | COMPLETED | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma |
| NCT01730157 | EARLY_PHASE1 | TERMINATED | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases |
| NCT02336763 | Not specified | TERMINATED | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DACARBAZINE | 4 | 2 |
| SARGRAMOSTIM | 4 | 2 |
| SUNITINIB | 4 | 2 |
| SELUMETINIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| TYROSINASE | 3 | 3 |
| GP-100 ANTIGEN | 3 | 2 |
| INCOMPLETE FREUND’S ADJUVANT | 3 | 2 |
| AGATOLIMOD SODIUM | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CIXUTUMUMAB | 2 | 1 |
| CHEMBL2369717 | 0 | 3 |
| CHEMBL1574179 | 0 | 2 |
| CHEMBL4463209 | 0 | 1 |